Brief: Edgewise Therapeutics Reports Positive Results On Sevasemten Program
26/06/2025 11:02
June 26 (Reuters) - Edgewise Therapeutics Inc EWTX.O: EDGEWISE THERAPEUTICS REPORTS POSITIVE RESULTS ON SEVASEMTEN PROGRAM FOR BECKER AND DUCHENNE MUSCULAR DYSTROPHIES EDGEWISE THERAPEUTICS INC - TO MEET WITH FDA IN Q4 2025 TO DISCUSS PHASE 3 DESIGN EDGEWISE THERAPEUTICS INC - NEW DATA SHOWS SUSTAINED DISEASE STABILIZATION IN BECKER UP TO THREE YEARS EDGEWISE THERAPEUTICS INC - PHASE 2 OBSERVATIONS IN DUCHENNE DEFINE DOSE FOR PHASE 3 Source text: ID:nPn28zVJka Further company coverage: EWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending